More MS news articles for May 2001

Protein Design Labs Announces Development of SMART(TM) Anti-IL-12 Antibody

http://www.individual.com/browse/story.shtml?story=p0502160.501&level1=46610&level2=46618&level3=2917&date=20010503

May 3, 2001
FREMONT, Calif., May 2 /PRNewswire/ via NewsEdge Corporation -

Protein Design Labs, Inc. (Nasdaq: PDLI) (PDL, the "Company") today announced that it has begun preclinical development of its SMART Anti-IL-12 Antibody. SMART Anti-IL-12 Antibody was humanized at PDL from a murine anti-IL-12 antibody that was licensed, together with certain intellectual property related to anti-IL-12 therapy, from Hoffmann-La Roche Inc. Financial terms of the license agreement were not disclosed.

"IL-12 is a cytokine that may have considerable potential as a target in the therapy of autoimmune diseases," said Cary Queen, Ph.D., PDL Senior Vice President and Vice President, Research. "Many autoimmune diseases are thought to be mediated by Th1 cells, a type of T cell that is generated in the presence of IL-12. Antibodies against IL-12 have been highly effective in reducing disease severity in animal models of multiple sclerosis, rheumatoid arthritis, psoriasis and inflammatory bowel disease."

"The humanized anti-IL-12 antibody is an important addition to PDL's already strong pipeline of humanized antibodies being developed for the treatment of autoimmune diseases," said Daniel Levitt, M.D., Ph.D., PDL President, Research and Development. "Autoimmune diseases involve complex immunological pathways, and we believe that development of several antibodies which are directed at different targets in these pathways is the approach most likely to result in successful therapies."

PDL currently has three other humanized antibodies in clinical trials for various autoimmune diseases. Zenapax(R) (Daclizumab) is in a Phase II trial for maintenance therapy in psoriasis, as well as in additional trials for Type I diabetes, multiple sclerosis, and Behcet's disease, a form of uveitis. Nuvion(TM) (SMART Anti-CD3) is in a Phase I/II trial for the acute treatment of psoriasis, and is expected to enter a trial in inflammatory bowel disease shortly. SMART Anti-Gamma Interferon is in a Phase I/II trial for the treatment of Crohn's disease, one form of inflammatory bowel disease.

The foregoing contains forward-looking statements involving risks and uncertainties and PDL's actual results may differ materially from those in the forward-looking statements. Factors that may cause such differences are discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2000. In particular, there can be no assurance that animal models will be predictive of results in humans, that the preclinical development of SMART Anti-IL-12 Antibody will be successful, that this or any of PDL's antibodies in development will advance to later stage clinical trials, or that these trials will show the antibodies to be safe and effective.

Protein Design Labs, Inc. is a leader in the development of humanized antibodies to prevent or treat various disease conditions. PDL currently has antibodies under development for autoimmune and inflammatory conditions, asthma and cancer. PDL has been issued fundamental patents covering its antibody humanization technology. For further information, visit www.pdl.com.

NOTE: Protein Design Labs and the PDL logo are registered U.S. trademarks and SMART and Nuvion are U.S. trademarks of Protein Design Labs, Inc. Zenapax is a registered U.S. trademark of Hoffmann-La Roche Inc.

SOURCE Protein Design Labs, Inc.

CONTACT: Robert L. Kirkman, M.D., Vice President, Business Development and Corporate Communications of Protein Design Labs, Inc., 510-574-1419, or rkirkman@pdl.com

Web site: http://www.pdl.com (PDLI)